Author

Michelle A. Seaberg

Observed names: M Seaberg, M.A. Seaberg, Michelle Seaberg, Seaberg, Michelle A.

Observed institutions: University of Freiburg, Alpine Immune Sciences (United States)

ORCID: 0000-0002-7772-773X

Observed ORCID: 0000-0002-7772-773X

OpenAlex ID: A5016713210

Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia

1995 · SD Lyman, M Seaberg, et al. · Blood · 115

Povetacicept, an Enhanced Dual APRIL / BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases

2023 · Lawrence S. Evans, Katherine E. Lewis, et al. · Arthritis & Rheumatology · 79

ICOSL + plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist

2020 · Djamilatou Adom, Stacey R. Dillon, et al. · Science Translational Medicine · 28

Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models

2022 · Cindy Orvain, Anne Cauvet, et al. · Arthritis Research & Therapy · 27

Op0039 Alpn-303, an Enhanced, Potent Dual Baff/april Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (sle) and Other B Cell-related Autoimmune Diseases

2021 · S.R. Dillon, L.S. Evans, et al. · Annals of the Rheumatic Diseases · 5

A Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgD) Potently Suppresses Human Mixed Lymphocyte Reactions and Human/NSG Mouse Xenograft Graft vs. Host Disease (GvHD)

2018 · Stacey R. Dillon, Katherine E. Lewis, et al. · Transplantation and Cellular Therapy · 3

OP0282 POVETACICEPT (ALPN-303; TACI vTD-Fc), AN ENHANCED, POTENT DUAL INHIBITOR OF BAFF AND APRIL, DEMONSTRATES GREATER TISSUE DISTRIBUTION VERSUS WILD-TYPE TACI-Fc IN ADULT MICE AND IMPROVED EFFICACY VERSUS WILD-TYPE TACI-Fc OR ANTI-CD20 IN THE IFNα-ACCELERATED NZB/W MOUSE MODEL OF SLE

2024 · K.E. Lewis, Z. Maria, et al. · Annals of the Rheumatic Diseases · 1

Povetacicept Displays Enhanced Serum Exposure and Improved Tissue Distribution Relative to Wild-Type TACI-Fc Molecules

2026 · Stacey R. Dillon, Shyamesh Kumar, et al. · Journal of Pharmacology and Experimental Therapeutics

Abstract 1740: Engineered variant domain fusion proteins provide checkpoint inhibition and tumor antigen dependent CD28 costimulation resulting in potent anti-tumor immunity

2021 · Steven D. Levin, Mark F. Maurer, et al. · Cancer Research

Thu0222 B Cell Modulatory Variant Tnf Receptor Domains (vtds) Identified by Directed Evolution to Inhibit Baff and April, Alone or Combined With Variant Ig Domains (vigd™) That Inhibit T Cell Costimulation, for the Treatment of Severe Autoimmune And/or Inflammatory Disease

2020 · S.R. Dillon, L.S. Evans, et al. · Annals of the Rheumatic Diseases

Works count: 16

Citation count: 258

H-index: 5

I10-index: 4